Gamma-glutamyltransferase as an indicator of hepatic tumor burden in neuroendocrine tumors

#3553

Introduction: In patients with neuroendocrine tumors (NETs) and liver metastasis, elevation of gamma-glutamyltransferase (GGT) is considered to be a sign of hepatic progression. However, there are no data supporting this assumption.

Aim(s): The aim of this study was to investigate the correlation between GGT and hepatic tumor burden and its value as a follow-up parameter.

Materials and methods: We retrospectively analysed n=104 patients with hepatic metastasized NET consulting our center between 12/2008 and 04/2021 (mean age 62.3 ± 12.6, 58.7% male). GGT levels were identified within 3 months of staging, excluding confounding factors, and radiologic reassessment was performed. Furthermore, we analysed the course of GGT levels and radiographic response in a small longitudinal sample of n=12 patients undergoing STZ/5FU therapy for pancreatic NET.

Conference:

Presenting Author: Schmidt B

Authors: Schmidt B, Leiderer M, Amin T, Viol F, Adam G,

Keywords: gamma glutamyltransferase, hepatic tumor burden, neuroendocrine tumor, liver metastasis, biomarker,